Biopharmaceutical company AstraZeneca Plc (STO:AZN) (LON:AZN) reported on Thursday the approval of Lokelma (sodium zirconium cyclosilicate) in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood).
Reportedly, this approval by Japan's Ministry of Health, Labour and Welfare was based on positive results from stand-alone studies in Japan and global clinical trial programmes. It was also supported by DIALIZE, a global trial for end-stage renal disease patients on haemodialysis, which demonstrated the positive efficacy and safety of Lokelma in the management of hyperkalaemia.
Lokelma is the first innovative non-resin potassium binder to be approved in Japan. Traditional resin-based binders are often associated with poor tolerability.
Also, Lokelma is approved for the treatment of hyperkalaemia in the US, EU, Canada, Hong Kong, China and Russia.
AstraZeneca is focused on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib